Clinical trial NCT06845046: A Study to Improve Skeletal Muscle in Veterans With HIV
Official title: A Randomized Trial to Optimize Skeletal Muscle While Reducing Adiposity in Veterans With HIV
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: HIV
Obesity
Keywords: HIV
obesity
skeletal muscle
dietary supplement
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2025-02-25
Enrollment: 70
Sex: MALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Randomization to one of 4 groups: Diet control group, Diet + w-3 supplement, Diet + L-carnitine supplement, Diet + w-3 + l-carnitine, followed by addition of resistance exercise training in each group, total intervention period is 4 weeks
Primary purpose: TREATMENT

Brief summary: The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obesity". Based on the investigators findings, the investigators have designed a multipronged integrated intervention that combines: 1) dietary replacement of saturated with unsaturated fats; 2) administration of L-carnitine and omega-3 fatty acid supplementation; and 3) targeted resistance exercise training.

Detailed description: The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. With the advances achieved in antiretroviral therapy (ART), Veterans with HIV now survive decades. However, this success is tempered by the rising burden of obesity now affecting 78% of Veterans. Defects in adipose tissue lipid storage and regulation are hallmarks of both treated HIV and obesity, which leads to a high degree of ectopic fat infiltrating organs and tissues such as skeletal muscle. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obesity". Further, the investigators found that high ectopic fat accumulation in muscle (quantified by CT imaging of skeletal muscle density) is associated with reduced mitochondrial oxidative capacity, greater inflammation, and impaired muscle glucose tolerance and insulin sensitivity. Hence the quality of muscle is just as important as the quantity of muscle. However, this important phenomenon has received little attention, especially in Veterans with HIV. Indeed, the need to target mobilizing and metabolizing skeletal muscle ectopic fat while preserving/increasing the total amount of skeletal muscle is most often overlooked and represents a major research gap and unmet clinical need. From the investigators current Merit Award funded study, the investigators have an established collaboration of experienced VA researchers with expertise in HIV and immunology, human nutrition and metabolism, endocrinology, radiology and imaging science, and muscle physiology. Based on the investigators findings, the investigators have designed a multipronged integrated intervention that combines: 1) dietary replacement of saturated with unsaturated fats; 2) administration of L-carnitine and omega-3 fatty acid supplementation; and 3) targeted resistance exercise training. This evidence-based intervention is designed to: a) increase lipid flux by facilitating the transfer of long-chain fatty acids into muscle mitochondria for -oxidation; b) decrease muscle proteolysis; and c) lessen insulin resistance and inflammation. Using a mixed 2x4 factorial design trial design in a cohort of 60 Veterans who have HIV and obesity, this study will determine the main and interaction effects of the multi-pronged intervention on: skeletal muscle density, mitochondrial oxidative capacity, and fatty acid oxidation (Aim 1); glucose tolerance, insulin sensitivity, and inflammation (Aim 2); and cardiopulmonary exercise tolerance and physical function (Aim 3). Obesity in Veterans with treated HIV is a heterogeneous condition. The investigators current Merit research shows myosteatotic obesity is a distinct condition from visceral or steatotic or sarcopenic obesity, affected by different clinical factors. The investigators findings to date provide the foundation for a novel evidence-based intervention that has the potential for significant clinical impact on Veterans, including and beyond those with HIV. This proposal meets VA-ORD priorities to improve health behaviors, focus on underserved Veterans, and provide precision care.

Eligibility criteria: Inclusion Criteria:

* Veteran
* HIV+
* antiretroviral therapy = integrase strand transfer inhibitor for at least 3 months
* HIV-1 RNA \<50 copies/ml
* age = 20 yrs
* BMI 28-50 kg/m2

Exclusion Criteria:

* unstable body weight (gain or loss \> 5% over past 3 months)
* diagnosed mitochondrial disorder
* diagnosed type 1 or type 2 diabetes
* use of metformin or other anti-diabetic agents for pre-diabetes
* hemoglobin A1c of \>6.5% at screening visit
* inflammatory conditions or chronic corticosteroid use
* stage 3 or greater kidney disease
* dietary or herbal supplements known to affect body weight, muscle mass, or immune function
* MRI incompatibility
* inability to perform physical function tests due to anatomical limitations
* contradictions to CPET such as exercise-induced ischemia or supplemental oxygen

Primary outcomes:
measure: Myosteatosis
timeFrame: Week 24 and 44
measure: MixedMeal GTT
timeFrame: Week 24 and 44
measure: Physical Function
timeFrame: Week 24 and 44
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
state: Tennessee
Study officials:
affiliation: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
name: Heidi J Silver, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
name: John R Koethe, MD
role: PRINCIPAL_INVESTIGATOR
References: